Técnicas inovadoras de entrega transdérmica de fármacos na leishmaniose cutânea
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Dec 14, 2023
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Identificar os estudos que analisaram o uso de distintos sistemas de entrega transdérmica, tanto para novas substâncias com potencial leishmanicida, quanto para os fármacos incluídos no arsenal terapêutico para o tratamento da leishmaniose cutânea. Métodos: Para tanto, foram utilizadas as seguintes etapas: identificação do tema, formulação da pergunta norteadora, delimitação dos descritores e seleção das bases de dados, estabelecimento de critérios de exclusão e de inclusão dos trabalhos, busca da amostragem na literatura e pré-seleção dos trabalhos (leitura de resumos e títulos); leitura dos estudos selecionados e, por fim, a interpretação dos resultados. Resultados: Diante disso, foram encontrados 903 estudos, sendo 305 com os descritores “leishmaniasis” AND “drug delivery systems” e 598 com os descritores “leishmaniasis” AND “transdermal administration”. Desses, foram excluídos 820, após a leitura dos títulos e resumos e mais 67 após a leitura integral do trabalho. Após análise e leitura minuciosa foram selecionados 16 trabalhos. Considerações finais: Os estudos revisados neste artigo demonstram que os sistemas de entrega transdérmica têm se mostrado promissores e inovadores no tratamento da leishmaniose cutânea.
##plugins.themes.bootstrap3.article.details##
Como Citar
FialhoS. N., Branco JuniorA. G., OliveiraV. M. de, GouveiaA. de J., MartinezL. do N., FerreiraA. S., SilvaM. A. da, & TelesC. B. G. (2023). Técnicas inovadoras de entrega transdérmica de fármacos na leishmaniose cutânea. Revista Eletrônica Acervo Saúde, 23(12), e14307. https://doi.org/10.25248/reas.e14307.2023
Seção
Revisão Bibliográfica
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. ALISHAHI M, et al. Glucantime-loaded electrospun core-shell nanofibers composed of poly(ethylene oxide)/gelatin-poly(vinyl alcohol)/chitosan as dressing for cutaneous leishmaniasis. International Journal of Biological Macromolecules, 2020; 15(163): 288-297.
2. ASGARI Q, et al. Fabrication of amphotericin B-loaded electrospun core–shell nanofibers as a novel dressing for superficial mycoses and cutaneous leishmaniasis. International Journal of Pharmaceutics, 2021; 606: 120911.
3. BHOWMIK, D, et al. Recent Approaches in Transdermal Drug Delivery System. The Pharma Innovation Journal. J.,2013; 2(3): 99 – 108.
4. BOTELHO LLR, et al. O Método da Revisão Integrativa nos Estudos Organizacionais. Revista Eletrônica Gestão e Sociedade, 2011; 5(11): 121-136.
5. BRASIL. Ministério da Saúde. Casos de Leishmaniose Tegumentar. Brasil, Grandes Regiões e Unidades Federadas. 1990 a 2018. 2020a. Disponível em: https://www.saude.gov.br/images/pdf/2019/outubro/14/LT-Casos.pdf. Acesso em: 26 de julho, 2023.
6. BRASIL. MINISTÉRIO DA SAÚDE. Secretaria de Vigilância em Saúde. Nota Informativa nº 13/2020 – CGZV/DEIDT/SVS/MS. Brasília: Ministério da Saúde, 2020b. Disponível em: https://www.gov.br/saude/pt-br/media/pdf/2020/dezembro/17/notainformativamiltefosina.pdf. Acesso realizado em 23 de julho de 2023.
7. COELHO D, et al. Polyvinyl alcohol-based electrospun matrix as a delivery system for nanoemulsion containing chalcone against Leishmania (Leishmania) amazonensis, Colloids and Surfaces B: Bioint, 2021; 198: e111390.
8. COSTA AMB, et al. Sistema termossensível formado por poloxâmeros contendo carvacrol: um sistema carreador eficaz contra Leishmania amazonensis. Acta Tropica, 2023; 237: e106744.
9. DHIMAN S, et al. Transdermal patches: a recent approach to new drug delivery system. Inter. J. Pharm. Pharmaceut. Scien., 2011; 3(5): 26-34.
10. EBRAHIMISADR P, et al. Effect of Polyvinyl Alcohol (PVA) Containing Artemether in Treatment of Cutaneous Leishmaniasis Caused by Leishmania major in BALB/c Mice. Jundishapur Journal of Microbiology, 2014; 7(5): e9696.
11. FLETCHER RH, et al. Epidemiologia clínica: elementos essenciais. 3 ed. Porto Alegre: Artes Médicas, 1996; 281p.
12. HAMIDIAN H e TAVAKOLI T. Preparation of a new Fe 3 O 4 /starch- g -polyester nanocomposite hydrogel and a study on swelling and drug delivery properties. Carbohydrate Polymers, 2016; 144: 140–148.
13. HIGUITA-CASTRO J, et al. Development of a biocompatible polymeric chitosan system for the release of compounds with leishmanicidal activity. Materials & Design, 2021; 212: e110232.
14. KHAN AU, et al. Designing, Optimization and Characterization of Trifluralin Transfersomal Gel to Passively Target Cutaneous Leishmaniasis. Journal of Pharmaceutical Sciences, 2022 ; 111(6) : 1798-1811.
15. MALI AD, et al. An updated review on transdermal drug delivery systems. International Journal of Advanced Science and Research, 2015; 1(6): 244.
16. MENDES EV. As Redes de Atenção à Saúde. Ciênc. Saúd. Colet.,2010; 15(5): 2297-2305.
17. MENEZES J, et al. Advances in Development of New Treatment for Leishmaniasis. BioMed Research International, 2015; 1(11): e101155.
18. LANZA JS, et al. TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. International Journal of Pharmaceutics, 2020; 30(586): e119390.
19. PEIXOTO JF, et al. Development of a microemulsion loaded with epoxy-α-lapachone against Leishmania (Leishmania) amazonensis murine infection. International Journal of Pharmaceutics, 2023; 636: e122864.
20. PEPPAS NA, et al. R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Advanced Materials, 2006;18(11): 1345-1360.
21. PEREZ AP, et al. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro. Colloids and Surfaces B: Biointerfaces, 2016; 139: 190–198.
22. PEZZINI BR, et al. Formas farmacêuticas sólidas orais de liberação prolongada: sistemas monolíticos e multiparticulados. Brazilian Journal of Pharmaceutical Sciences, 2007; 43(4): 491–502.
23. PINHEIRO IM, et al. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis. Experimental Parasitology, 2016; 164: 49–55.
24. SANTIAGO AS, et al. Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review. Research, Society and Development, 2021; 10(7): e29510716543.
25. SCHWARTZ J, et al. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation. European Journal of Pharmaceutical Sciences, 2014; 62: 309–316.
26. SHARMA A, et al. Transdermal drug delivery system: a review. International Journal of Research in Pharmaceutical and Biomedical, 2018; 7(7): 260-288.
27. SILVA MA, et al. Antileishmanial activity evaluation of a natural amide and its synthetic analogs against Leishmania (V.) braziliensis: an integrated approach in vitro and in silico. Parasitology Research., 2021; 120: 2199–2218.
28. SILVEIRA LMC e RIBEIRO VMB. Compliance with treatment groups: a teaching and learning arena for healthcare professionals and patients. Interface – Comunicação, Saúde, Educação, 2005; 9(16): 91-104.
29. TIWARI N, et al. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis. Mini-Reviews in Medicinal Chemistry, 2018; 18(1): 91–104.
30. ULIANA SRB, et al. Chemotherapy of leishmaniasis: present challenges. Parasitology, 2018; 145(4): 464-480.
31. VAN BOCXLAER K, et al. Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis. Pharmaceutics, 2021; 13(4): e516.
32. YADAV V. Transdermal drug delivery system: review. International Journal of Pharmaceutical Sciences and Research, 2012; 3(2): 376-382.
33. ZARE MR, et al. Dissolvable carboxymethyl cellulose/polyvinylpyrrolidone microneedle arrays for transdermal delivery of Amphotericin B to treat cutaneous leishmaniasis. International Journal of Biological Macromolecules, 2021; 182: 1310–1321.
2. ASGARI Q, et al. Fabrication of amphotericin B-loaded electrospun core–shell nanofibers as a novel dressing for superficial mycoses and cutaneous leishmaniasis. International Journal of Pharmaceutics, 2021; 606: 120911.
3. BHOWMIK, D, et al. Recent Approaches in Transdermal Drug Delivery System. The Pharma Innovation Journal. J.,2013; 2(3): 99 – 108.
4. BOTELHO LLR, et al. O Método da Revisão Integrativa nos Estudos Organizacionais. Revista Eletrônica Gestão e Sociedade, 2011; 5(11): 121-136.
5. BRASIL. Ministério da Saúde. Casos de Leishmaniose Tegumentar. Brasil, Grandes Regiões e Unidades Federadas. 1990 a 2018. 2020a. Disponível em: https://www.saude.gov.br/images/pdf/2019/outubro/14/LT-Casos.pdf. Acesso em: 26 de julho, 2023.
6. BRASIL. MINISTÉRIO DA SAÚDE. Secretaria de Vigilância em Saúde. Nota Informativa nº 13/2020 – CGZV/DEIDT/SVS/MS. Brasília: Ministério da Saúde, 2020b. Disponível em: https://www.gov.br/saude/pt-br/media/pdf/2020/dezembro/17/notainformativamiltefosina.pdf. Acesso realizado em 23 de julho de 2023.
7. COELHO D, et al. Polyvinyl alcohol-based electrospun matrix as a delivery system for nanoemulsion containing chalcone against Leishmania (Leishmania) amazonensis, Colloids and Surfaces B: Bioint, 2021; 198: e111390.
8. COSTA AMB, et al. Sistema termossensível formado por poloxâmeros contendo carvacrol: um sistema carreador eficaz contra Leishmania amazonensis. Acta Tropica, 2023; 237: e106744.
9. DHIMAN S, et al. Transdermal patches: a recent approach to new drug delivery system. Inter. J. Pharm. Pharmaceut. Scien., 2011; 3(5): 26-34.
10. EBRAHIMISADR P, et al. Effect of Polyvinyl Alcohol (PVA) Containing Artemether in Treatment of Cutaneous Leishmaniasis Caused by Leishmania major in BALB/c Mice. Jundishapur Journal of Microbiology, 2014; 7(5): e9696.
11. FLETCHER RH, et al. Epidemiologia clínica: elementos essenciais. 3 ed. Porto Alegre: Artes Médicas, 1996; 281p.
12. HAMIDIAN H e TAVAKOLI T. Preparation of a new Fe 3 O 4 /starch- g -polyester nanocomposite hydrogel and a study on swelling and drug delivery properties. Carbohydrate Polymers, 2016; 144: 140–148.
13. HIGUITA-CASTRO J, et al. Development of a biocompatible polymeric chitosan system for the release of compounds with leishmanicidal activity. Materials & Design, 2021; 212: e110232.
14. KHAN AU, et al. Designing, Optimization and Characterization of Trifluralin Transfersomal Gel to Passively Target Cutaneous Leishmaniasis. Journal of Pharmaceutical Sciences, 2022 ; 111(6) : 1798-1811.
15. MALI AD, et al. An updated review on transdermal drug delivery systems. International Journal of Advanced Science and Research, 2015; 1(6): 244.
16. MENDES EV. As Redes de Atenção à Saúde. Ciênc. Saúd. Colet.,2010; 15(5): 2297-2305.
17. MENEZES J, et al. Advances in Development of New Treatment for Leishmaniasis. BioMed Research International, 2015; 1(11): e101155.
18. LANZA JS, et al. TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. International Journal of Pharmaceutics, 2020; 30(586): e119390.
19. PEIXOTO JF, et al. Development of a microemulsion loaded with epoxy-α-lapachone against Leishmania (Leishmania) amazonensis murine infection. International Journal of Pharmaceutics, 2023; 636: e122864.
20. PEPPAS NA, et al. R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Advanced Materials, 2006;18(11): 1345-1360.
21. PEREZ AP, et al. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro. Colloids and Surfaces B: Biointerfaces, 2016; 139: 190–198.
22. PEZZINI BR, et al. Formas farmacêuticas sólidas orais de liberação prolongada: sistemas monolíticos e multiparticulados. Brazilian Journal of Pharmaceutical Sciences, 2007; 43(4): 491–502.
23. PINHEIRO IM, et al. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis. Experimental Parasitology, 2016; 164: 49–55.
24. SANTIAGO AS, et al. Leishmaniasis treatment, current therapy limitations and new alternative requirements: A narrative review. Research, Society and Development, 2021; 10(7): e29510716543.
25. SCHWARTZ J, et al. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation. European Journal of Pharmaceutical Sciences, 2014; 62: 309–316.
26. SHARMA A, et al. Transdermal drug delivery system: a review. International Journal of Research in Pharmaceutical and Biomedical, 2018; 7(7): 260-288.
27. SILVA MA, et al. Antileishmanial activity evaluation of a natural amide and its synthetic analogs against Leishmania (V.) braziliensis: an integrated approach in vitro and in silico. Parasitology Research., 2021; 120: 2199–2218.
28. SILVEIRA LMC e RIBEIRO VMB. Compliance with treatment groups: a teaching and learning arena for healthcare professionals and patients. Interface – Comunicação, Saúde, Educação, 2005; 9(16): 91-104.
29. TIWARI N, et al. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis. Mini-Reviews in Medicinal Chemistry, 2018; 18(1): 91–104.
30. ULIANA SRB, et al. Chemotherapy of leishmaniasis: present challenges. Parasitology, 2018; 145(4): 464-480.
31. VAN BOCXLAER K, et al. Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis. Pharmaceutics, 2021; 13(4): e516.
32. YADAV V. Transdermal drug delivery system: review. International Journal of Pharmaceutical Sciences and Research, 2012; 3(2): 376-382.
33. ZARE MR, et al. Dissolvable carboxymethyl cellulose/polyvinylpyrrolidone microneedle arrays for transdermal delivery of Amphotericin B to treat cutaneous leishmaniasis. International Journal of Biological Macromolecules, 2021; 182: 1310–1321.